UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                    FORM 10-Q



     |X|  QUARTERLY  REPORT  PURSUANT  TO SECTION 13 OR 15(D) OF THE  SECURITIES
                              EXCHANGE ACT OF 1934

                                       OR

     |_|  TRANSITION  REPORT  PURSUANT TO SECTION 13 OR 15(D) OF THE  SECURITIES
                              EXCHANGE ACT OF 1934


                         Commission File Number: 1-10768


                       MEDIWARE INFORMATION SYSTEMS, INC.
             (Exact name of registrant as specified in its charter)


            New York                                             11-2209324
  (State or other jurisdiction of                            (I.R.S. Employer
   incorporation or organization)                           Identification No.)


        1121 Old Walt Whitman Road
             Melville, New York                                  11747-3005
  (Address of principal executive offices)                       (Zip Code)

                                 (516) 423-7800
               (Registrant's telephone number including area code)


--------------------------------------------------------------------------------
              (Former name, former address and former fiscal year,
                         if changed since last report)


Indicate  by check mark  whether  the  registrant  has filed all  documents  and
reports  required  to be filed by  Sections  12,  13 or 15(d) of the  Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter  period
that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days. Yes _X_  No ___

As of February 10, 2000, there were 6,962,790 shares of Common Stock,  $0.10 par
value, of the registrant outstanding.


<PAGE>


MEDIWARE INFORMATIONS SYSTEMS, INC.


                                      INDEX
                                                                            Page
                                                                            ----

PART I   Financial Information

ITEM 1.  Financial Statements

         Consolidated Balance Sheets as of December 31, 1999
         (Unaudited) and June 30, 1999 (Audited) ............................  3

         Consolidated Statements of Operations and Comprehensive Income
         For the three and six months ended December 31,
         1999 and 1998 (Unaudited) ..........................................  4

         Consolidated Statements of Cash Flows
         For the six months ended
         December 31, 1999 and 1998 (Unaudited) .............................  5

         Notes to Financial Statements  .....................................  6

ITEM 2.  Management's Discussion and Analysis of Financial
         Condition and Results of Operations.................................  7


ITEM 3.  Quantitative and Qualitative Disclosures About Market Risks......... 10


PART II  Other Information

ITEM 2.  Sales of Securities Not Registered Under the
         Securities Act of 1933 ............................................. 10

ITEM 6.  Exhibits and Reports on Form 8-K  .................................. 10


Signature Page  ............................................................. 11


Exhibit 11

Schedule of Computation of Net Income (Loss) Per Share ...................... 12

Exhibit 27

Financial Data Schedule ..................................................... 13



                                       2
<PAGE>



               MEDIWARE INFORMATION SYSTEMS, INC. AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEETS
                      (Amounts in thousands, except shares)

<TABLE>
<CAPTION>
                                                             December 31,    June 30,
                                                                1999           1999
                                                             ------------    --------
                                                             (Unaudited)    (Audited)
<S>                                                           <C>            <C>
ASSETS
Current Assets
     Cash and cash equivalents                                $  3,465      $  3,556
     Accounts receivable (net of allowance of $777 at
      December 31, 1999 and $907 at June 30, 1999)               8,591         8,361
     Inventories                                                   475           403
     Prepaid expenses and other current assets                     451           568
     Deferred tax asset                                            448           448
                                                              --------      --------
        Total current assets                                    13,430        13,336
                                                              --------      --------
Fixed assets, net                                                1,901         1,883
Capitalized software costs, net                                  5,510         4,289
Goodwill, net                                                    6,062         6,266
Purchased technology, net                                        1,950           448
Other long-term assets                                             140           126
                                                              --------      --------
        Total Assets                                          $ 28,993      $ 26,348
                                                              ========      ========

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
     Notes payable and current portion of long-term debt      $  1,104      $  1,137
     Accounts payable                                            1,151         1,115
     Advances from customers                                     5,732         5,347
     Accrued expenses and other current liabilities              3,212         2,554
                                                              --------      --------
        Total current liabilities                               11,199        10,153

Other long-term liabilities                                        139           279
                                                              --------      --------
        Total liabilities                                       11,338        10,432
                                                              --------      --------

Stockholders' Equity
     Preferred stock, $.01 par value; authorized 10,000,000
      shares; none issued or outstanding                          --            --
     Common stock, $.10 par value; authorized 12,000,000
      shares; issued and outstanding; 6,969,000 shares at
      December 31, 1999 and 6,146,000 at June 30, 1999             697           615
     Additional paid-in capital                                 22,298        21,421
     Accumulated deficit                                        (5,313)       (6,107)
     Unearned compensation                                        --             (11)
     Accumulated other comprehensive (loss)                        (27)           (2)
                                                              --------      --------
        Total stockholders' equity                              17,655        15,916
                                                              --------      --------
        Total Liabilities and Stockholders' Equity            $ 28,993      $ 26,348
                                                              ========      ========
</TABLE>


                 See Notes to Consolidated Financial Statements.



                                       3
<PAGE>



               MEDIWARE INFORMATION SYSTEMS, INC. AND SUBSIDIARIES
         CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
                                   (Unaudited)
                (Amounts in thousands, except per share amounts)


<TABLE>
<CAPTION>
                                                          Three Months Ended         Six Months Ended
                                                             December 31,              December 31,
                                                          -------------------     --------------------
                                                            1999        1998        1999         1998
                                                          --------    --------    --------    --------
<S>                                                       <C>         <C>         <C>         <C>
Revenues
      System sales                                        $  2,062    $  3,039    $  4,384    $  5,962
      Services                                               4,992       3,897       9,673       7,102
                                                          --------    --------    --------    --------
         Total revenues                                      7,054       6,936      14,057      13,064
                                                          --------    --------    --------    --------

Cost and Expenses
      Cost of systems                                          843         916       1,555       1,817
      Cost of services                                       1,522       1,085       3,099       1,992
      Purchased research and development                      --          --          --         4,553
      Software development costs                               989         858       2,111       1,521
      Selling, general and administrative                    3,034       3,055       6,079       5,663
                                                          --------    --------    --------    --------
         Total costs and expenses                            6,388       5,914      12,844      15,546
                                                          --------    --------    --------    --------

         Operating income (loss)                               666       1,022       1,213      (2,482)

Interest and other income                                       28          29          66          70
Interest (expense)                                             (17)        (13)        (37)       (106)
                                                          --------    --------    --------    --------
      Earnings (loss) before provision for income taxes        677       1,038       1,242      (2,518)
Provision for income taxes                                    (244)       (155)       (448)       (305)
                                                          --------    --------    --------    --------

         Net Earnings (Loss)                                   433         883         794      (2,823)
                                                          --------    --------    --------    --------

Other Comprehensive Income, net of tax
      Foreign currency translation adjustment                  (15)       --           (27)       --
                                                          --------    --------    --------    --------

         Comprehensive Income (Loss)                      $    418    $    883    $    767    $ (2,823)
                                                          ========    ========    ========    ========

Earnings (Loss) Per Common Share
      Basic                                               $   0.07    $   0.15    $   0.13    $  (0.48)
                                                          ========    ========    ========    ========

      Diluted                                             $   0.06    $   0.13    $   0.11    $  (0.48)
                                                          ========    ========    ========    ========

Weighted Average Common Shares Outstanding
      Basic                                                  6,344       6,049       6,258       5,840
                                                          ========    ========    ========    ========

      Diluted                                                7,201       7,057       7,176       5,840
                                                          ========    ========    ========    ========
</TABLE>



                 See Notes to Consolidated Financial Statements.


                                       4
<PAGE>


               MEDIWARE INFORMATION SYSTEMS, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (Unaudited)
                             (Amounts in thousands)

<TABLE>
<CAPTION>
                                                                              Six Months Ended December 31,
                                                                              -----------------------------
                                                                                     1999       1998
                                                                                   -------    -------
<S>                                                                                <C>        <C>
Cash Flows From Operating Activities
    Net earnings (loss)                                                            $   794    $(2,823)
    Adjustments to reconcile net earnings (loss) to
     net cash provided by operating activities:
       Depreciation and amortization                                                 1,096        653
       Write-off of acquired research and development                                 --        4,553
       Shares issued to directors                                                       50         50
       Compensatory stock options                                                       11         20
       Provision for doubtful accounts                                                  99         15
    Changes in operating assets and liabilities:
       Accounts receivable                                                            (329)    (1,352)
       Inventories                                                                     (72)        11
       Prepaid and other                                                               103       (232)
       Accounts payable, accrued expenses and
        customer advances                                                              314      1,248
                                                                                   -------    -------
    Net cash provided by operating activities                                        2,066      2,143
                                                                                   -------    -------

Cash Flows From Investing Activities
    Acquisition of fixed assets                                                       (305)      (665)
    Capitalized software costs                                                      (1,793)      (714)
    Acquisition of technology                                                         (785)      --
    Acquisition of Informedics                                                        --          653
                                                                                   -------    -------
    Net cash used in investing activities                                           (2,883)      (726)
                                                                                   -------    -------

Cash Flows From Financing Activities
    Principal payments of long-term debt and
     capitalized leases                                                               (158)    (3,750)
    Proceeds from exercise of options and warrants                                     909         38
                                                                                   -------    -------
    Net cash provided by (used in) financing activities                                751     (3,712)
                                                                                   -------    -------

    Foreign currency translation adjustments                                           (25)        (2)
                                                                                   -------    -------

    Net (Decrease) in Cash and Cash Equivalents                                        (91)    (2,297)

    Cash and cash equivalents at beginning of period                                 3,556      4,681

                                                                                   -------    -------
    Cash and cash equivalents at end of period                                     $ 3,465    $ 2,384
                                                                                   =======    =======


Supplemental  disclosures of cash flow information
  Cash paid during the period for:
      Interest                                                                     $    94    $    98
      Income taxes                                                                 $   127    $    71

Non-cash investing activities:
   Accounts payable related to the purchase of technology                          $   750    $  --

</TABLE>


                 See Notes to Consolidated Financial Statements.


                                       5


<PAGE>


              MEDIWARE INFORMATION SYSTEMS, INC., AND SUBSIDIARIES
                     NOTES TO UNAUDITED FINANICAL STATEMENTS


1.   FINANCIAL STATEMENTS

In  the  opinion  of  management,  the  accompanying  unaudited,   consolidated,
condensed  financial  statements  contain all  adjustments  necessary to present
fairly the financial  position of the Company and its results of operations  and
cash flows for the interim  periods  presented.  Such financial  statements have
been condensed in accordance  with the applicable  regulations of the Securities
and Exchange  Commission  ("SEC") and therefore,  do not include all disclosures
required by generally accepted accounting principles. These financial statements
should be read in conjunction with the Company's  audited  financial  statements
for the year ended June 30, 1999 included in the  Company's  annual report filed
on Form 10-KSB.

The results of operations  for the three and six months ended  December 31, 1999
are not  necessarily  indicative  of the results to be  expected  for the entire
fiscal year.

2.   EARNINGS (LOSS) PER SHARE

Basic earnings per share have been computed using the weighted average number of
shares of common  stock of the Company  ("Common  Stock")  outstanding  for each
period presented.  For the three and six months ended December 31, 1999, and the
three months ended December 31, 1998,  the dilutive  effect of stock options and
other  common  stock  equivalents  is  included  in the  calculation  of diluted
earnings per share using the  treasury  stock  method.  For the six months ended
December 31, 1998,  common stock equivalents are not included in the calculation
of loss per share as the effect would be anti-dilutive.

3.   ACQUISITIONS

In September,  1998, the Company acquired Informedics,  Inc.  ("Informedics") in
exchange for 439,525  shares of the  Company's  common stock on the basis of one
Company  share  for each  6.3  shares  of  Informedics'  stock.  The cost of the
acquisition,  which was  accounted  for as a  purchase,  aggregated  $7,100,000,
including  acquisition costs of $801,000,  assumed liabilities of $1,599,000 and
$4,700,000 of common stock issued and options assumed (based on the market price
of  the  Company's  common  stock  in  December  1997,  when  the  terms  of the
acquisition  agreement were agreed to). Assets acquired  aggregated  $2,547,000,
including $917,000 of goodwill, $498,000 of technology and $653,000 of cash.

In November  1999,  the  company  executed an  agreement  with Carter  BloodCare
(Dallas,  Texas) for the purchase of LifeTrak(TM),  a comprehensive blood center
software package. LifeTrak(TM) was developed by Carter BloodCare and has been in
use there for over three years. The  LifeTrak(TM)  Lab and Distribution  modules
were 510(k)  cleared by the Food and Drug  Administration  ("FDA")  prior to the
acquisition.  In December 1999, the Donor module received FDA 510(k)  clearance.
The Company is marketing  LifeTrak(TM) on a world-wide basis. The purchase price
aggregated $1,500,000, including $750,000 paid upon delivery of the product, and
installments  of $375,000 due upon  clearance by the FDA of the Donor system and
on June 30, 2000.


                                       6
<PAGE>


The Company also entered into a license agreement  granting Carter BloodCare the
right to  continue  use of the  software in their  blood  center and  laboratory
facilities,  and  providing for  additional  purchase  price  payments to Carter
BloodCare by the Company in an amount equivalent to 5% of LifeTrak(TM)  software
sales for a five-year  term. The  purchase  price was  attributed  to  purchased
technology which is being amortized over its expected useful life of five years.

4.   RELATED PARTY TRANSACTIONS

During the  quarter  ended  December  31,  1999,  the  Chairman  of the Board of
Directors  executed a total of 674,695 stock  warrants and 15,000 stock options,
increasing his ownership to 14.9% of the  outstanding  stock of the Company,  as
computed  under  Rule  13d-3 of the  Securities  and  Exchange  Commission.  The
warrants  exercised were  originally  issued in connection  with the fiscal 1995
bridge  financing at an exercise  price of $.50 per share for 545,000 shares and
$1.25 per share for 129,695 shares.  The stock options were exercised at a price
of $5.25 per share and were originally  granted as  compensation  for service as
the Chairman of the Board. The Company received  aggregate  proceeds of $513,369
upon the above mentioned exercise.

ITEM 2. MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF OPERATIONS

Forward-Looking Statements

Certain  statements  made in or  incorporated  into  this  10-Q  may  constitute
"forward-looking"  statements  within  the  meaning  of the  Private  Securities
Litigation Reform Act of 1995, as the same may be amended from time to time (the
"Act") and in releases made by the SEC from time to time.  Such  forward-looking
statements  are not based on  historical  facts and  involve  known and  unknown
risks, uncertainties and other factors which may cause the actual results of the
Company to be materially  different from any future results expressed or implied
by such forward-looking  statements.  These risks and uncertainties include: (i)
fluctuations  in  quarterly  operating  results,  (ii)  reliance  on third party
software, (iii) dependence on third party marketing relationships,  (iv) changes
in the healthcare  industry,  (v)  significant  competition,  (vi) the Company's
ability to manage its rapid growth, (vii) the effects of government  regulations
on the Company,  (viii) product related liabilities,  (ix) risks associated with
system errors and  warranties.  Amplification  of such risks may be found in the
"Management's  Discussion  and  Analysis of Financial  Condition  and Results of
Operations" section of the Company's Annual Report on Form 10-KSB for the fiscal
year ended June 30,  1999.  The Company  does not intend to update  publicly any
forward-looking statements.

Results of Operations

Total  Company  revenues  increased by 1.7% or $118,000 and 7.6% or $993,000 for
the three and six months ended December 31, 1999,  respectively,  as compared to
the same periods a year ago. For the  quarter,  increased  revenues in the Blood
Bank and JAC divisions were offset by flat or declining revenues in the Pharmacy
and Operating  Room  divisions as a result of declines in new system sales.  The
year-to-date  increase in revenues is primarily  attributable  to an increase in
service  revenues  and a full six months of  operations  during  fiscal 2000 for
Informedics, which was acquired late in the first quarter of fiscal 1999.

System sales  decreased 32% or $977,000 and 26.5% or $1,578,000  for the quarter
and  year-to-date  periods compared to fiscal 1999. The decrease in system sales
resulted primarily from a decrease in new business in the six-month period ended
December 31, 1999.  The Company  believes the system sales were  negatively  and
primarily  impacted by purchasing  decision  delays related to Year 2000 issues,
and additionally, by delays experienced in the delivery of new product releases.
Management  believes  that  interest in new system  purchases has increased as a
result of the passing of Y2K.  However,  there can be no assurances  that system
sales will rebound to levels seen prior to the publicly  reported  industry-wide
Y2K slowdown.


                                       7
<PAGE>


Service  revenues  increased  28% or  $1,095,000  for the  quarter  and 36.2% or
$2,571,000 for the six months compared to last year.  Increases  occurred in all
product  lines  and are  attributable  to  increased  levels  of  implementation
activity related to Y2K upgrades and  implementation  of the Company's  WORx(TM)
Drug Therapy Management System to meet clients' Y2K deadlines. Additionally, the
year-to-date  increase  was  impacted  by a  full  six  months  of  Informedics'
operations.

Cost of systems includes the cost of computer hardware and sublicensed  software
purchased  from computer and software  manufacturers  by Mediware as part of its
complete  system  offering.  These  costs can vary as the mix of revenue  varies
between high margin proprietary  software and lower margin computer hardware and
sublicensed  software  components.  Cost of systems was 40.9% of related  system
sales for the second  quarter and 35.5% year to date compared to 30.1% and 30.5%
for the same  periods last year.  The increase in cost of systems was  primarily
driven by a higher volume of low margin product upgrades in preparation for Y2K.

Cost  of  services  includes  the  salaries  of  client  service  personnel  and
communications   expenses  along  with  the  direct  client  service  department
expenses. Cost of services increased by $437,000 or 40.3% for the second quarter
and $1,107,000 or 55.6% year to date compared to the same periods in fiscal 1999
on the  increase  in service  revenues  over last year.  As a percent of related
service revenues,  cost of services increased to 30.5% from 27.8% for the second
quarter and to 32.0% from 28.0% year to date.  This  increase in cost  primarily
reflects  an increase in  technical  field  installation  and  customer  support
activities related to the Company's Pharmacy and Blood Bank divisions.

Software development costs include salaries, consulting,  documentation,  office
and  other  related  expenses   incurred  in  product   development  along  with
amortization of software development costs. Software development costs increased
15.3% for the quarter to $989,000 and 38.9% for the six months to $2,111,000 for
the same  periods  last  year.  Total  expenditures  for  software  development,
including  both   capitalized   and   non-capitalized   portions  and  excluding
capitalized software amortization were $1,634,000 and $3,332,000,  respectively,
for the three and six months ended  compared to  $1,052,000  and  $2,044,000  in
fiscal 1999. The increased spending reflects  development costs for the Pharmacy
Division's  WORx product line,  significant  investing in new development of the
Company's core blood bank product offerings and, to a lesser degree, development
related to the Operating Room Division's  PCMWin,  Windows  client/server  based
line of products.

Selling,  general and  administrative  expenses remained fairly constant for the
quarter  compared  to last year at  $3,034,000  this year versus  $3,055,000  in
fiscal 1999.  For the six months ended December 31, 1999,  selling,  general and
administrative  expenses increased $416,000 or 7.3% to $6,079,000.  The increase
in cost was primarily due to increased  selling related  expenses as well as the
inclusion of a full six months of operations of the Informedics product center.

Interest expenses increased by 30.8% for the three months and decreased by 65.1%
for the six  months  ended  December  31,  1999,  compared  to the prior year to
$17,000 and $37,000 respectively. The


                                       8
<PAGE>


decrease  reflects the repayment  during fiscal 1999 of the outstanding  balance
remaining from the acquisition of the Pharmakon and JAC divisions of Continental
Healthcare Systems, Inc.

Net earnings were $433,000 for the quarter,  a 51% or $450,000  decline from the
second  quarter  last year.  For the  current  six months  ended,  net  earnings
increased  $3,617,000  to  $794,000  compared  to a net  loss of  $2,823,000  at
December 31, 1998.  Excluding a September  1998 one-time  charge for  in-process
research and development related to the acquisition of Informedics, net earnings
decreased $936,000 or 54.1%, from $1,730,000.

Capital Resources and Liquidity

As of December 31, 1999 the Company had cash and cash equivalents of $3,465,000,
a  decrease  of $91,000  from the fiscal  year end June 30,  1999.  Net  working
capital was $2,230,000 and the current ratio was 1:20:1.  The Company  generated
net cash from  operations  of  $2,066,000  and  $2,143,000  during the six-month
periods ended December 31, 1999 and 1998, respectively. The decrease in net cash
from operations is due to a decrease in net income resulting from a slow down in
software purchases by customers due to concerns about Year 2000 readiness.

The Company  invested  $2,883,000 and $726,000 during the six-month period ended
December  31,  1999  and  1998,  respectively.  The  principal  uses of cash for
investing  activities  during the current  period  included  purchases  of fixed
assets, investments in product development,  and the payment of $750,000 towards
the purchase of the  LifeTrak(TM)  blood center software  package to enhance the
Company's  suite of blood bank  product  offerings.  The  balance of $750,000 is
payable one-half upon 510(k) approval and one-half at June 30, 2000.  During the
period,  the Company  spent  $305,000 on  purchases  of fixed  assets  primarily
related to  equipment  and  software  to  accommodate  increases  in  employees,
upgrading aged systems and for use in product  development  activities.  For the
same period in 1998, fixed asset purchases of $665,000 were primarily related to
the  Pharmacy  office  relocation  and  expansion  of  facilities.  The  Company
capitalized  new product  development of $1,793,000 and $714,000 for the periods
ended  December  31, 1999 and 1998,  respectively.  The  investments  in product
development were related to continuing new development in the Pharmacy and Blood
Bank  divisions.  The  Company  plans to continue  enhancing  its  products  and
investing in its next generation information systems.

Cash flows from  financing  activities  for the period  ended  December 31, 1999
related to the exercise of options and warrants  which  aggregated  to $909,000.
Cash used in financing activities for the period ended December 31, 1999 include
a  repayment  of notes  payable to a  director  in the  amount of  $100,000  and
repayment of notes  payable to a  non-affiliate  in the amount of $50,000.  Cash
used in financing  activities  for the period ended December 1998 related to the
repayment of a  promissory  note issued to IHS  pursuant to the  acquisition  of
their Pharmakon and JAC  operations.  During the period ended December 31, 1999,
the Company received  $513,000 upon the exercise by the Chairman of the Board of
Directors of stock options and warrants totaling 690,000 shares of common stock.
Additionally,  the Company received  approximately $404,000 upon the exercise of
127,000 stock options.

Exclusive of activities  involving  acquisitions  of products or companies  that
complement  or augment the existing line of products,  management  believes that
existing  funds and cash generated  from  operations  will be sufficient to meet
operating  requirements  through  December  31, 2000.  However,  there can be no
assurances  the  Company  will  continue  to  operate  at  current  cash  levels
long-term,  and it may be necessary to seek financial  arrangements  to continue
the plan of significant  investments  into the Company's core product lines. The
Company's  liquidity  is  influenced  by the  Company's  ability to perform in a
competitive  industry  that  was  impacted  by  Y2K-readiness  concerns  and the
deferral of purchases and  implementations  of systems.  Factors that may affect
liquidity  are the  ability to  maintain  or improve  the sales  cycle,  and the
ability to collect cash from clients as implementations of systems progress.


                                       9
<PAGE>



ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

For a discussion of quantitative and qualitative disclosures about market risks,
please see the Management's  Discussion and Analysis of Financial  Condition and
Results of Operations  section of the Company's Annual Report on Form 10-KSB for
the fiscal year ended June 30, 1999.


PART II  OTHER INFORMATION

ITEM 2.  SALE OF SECURITIES NOT REGISTERED UNDER SECURITIES ACT OF 1933 ("Act")

                                   Number of Shares
          Date of Sale             of Common Stock             Consideration
          ------------             ----------------            -------------

        December 17, 1999              545,000                   $ 272,500
        December 17, 1999              129,695                   $ 162,119

No underwriters or other purchasers were involved.  All securities were sold for
cash upon the exercise of warrants to purchase  Common  Stock  acquired in 1995.
The sale of the above described  shares was exempt from  registration  under the
Act by  reason  of  Section  4(2) of the  Act.  All  shares  were  acquired  for
investment and not for distribution.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

(a). Exhibits

Exhibit 11.  Schedule of Computation of Net Income (Loss) Per Share

Exhibit 27.   Financial Data Schedule

(b). Reports on Form 8-K


No reports  on Form 8-K were  filed by the  Company  during  the  quarter  ended
December 31, 1999.


                                       10
<PAGE>


                                   SIGNATURES


Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                                        MEDIWARE INFORMATION SYSTEMS, INC.
                                        ----------------------------------
                                                 (Registrant)



February 18, 2000                        /s/ John Esposito
-----------------                        ---------------------------------------
    (Date)                               John Esposito
                                         President and Chief Executive Officer




February 18, 2000                         /s/ Kerry Robison
-----------------                         --------------------------------------
     (Date)                               Kerry Robison
                                          Chief Financial and Accounting Officer


                                       11